Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis

The optimal chemotherapy-free regimens for treatment-naive CLL still remains undefined. We searched relevant published reports. Three trials with 1017 subjects were identified. In the network meta-analysis, acalabrutinib plus obinutuzumab (Aca + Obi) improved PFS than ibrutinib plus obinutuzumab (Ib...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Leukemia & lymphoma Ročník 61; číslo 14; s. 3432 - 3439
Hlavní autoři:	Sheng, Zhixin, Song, Shilei, Yu, Miao, Zhu, Hongguang, Gao, Anran, Gao, Weijie, Ran, Xuehong, Huo, Da
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Taylor & Francis 05.12.2020
Témata:	Acalabrutinib Adenine - analogs & derivatives Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Benzamides Bridged Bicyclo Compounds, Heterocyclic Chlorambucil - therapeutic use chronic lymphocytic leukemia Humans ibrutinib Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy meta-analysis obinutuzumab Piperidines Prospective Studies Pyrazines Sulfonamides venetoclax ibrutinib meta-analysis chronic lymphocytic leukemia Acalabrutinib venetoclax obinutuzumab
ISSN:	1042-8194, 1029-2403, 1029-2403
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!